From a zero-landfill plant to the historic goal of a zero-landfill National Park system, experience over a decade of our enviromental ingenuity. Explore.
Interestingly, Abou-Elella et al (11) could not confirm that the clinical course of PMLBCL was distinct from diffuse large B-cell lymphoma (DLBCL). Treatment of the lymph node cancer called diffuse large B-cell lymphoma is all-or-nothing. Genes make potential target in lymph cancer. Despite this, indolent disease is typically incurable, with the most aggressive lymphoma subtype - diffuse large B-cell lymphoma having 5-year survival rates of -50%.
Rituximab in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) is the recommended first-line therapy for DLBCL. Carolina Reyes, PhD, of Genentech, San Francisco, CA, examined differences in treatment patterns, healthcare resource use, and costs among patients with DLBCL receiving rituximab plus chemotherapy in the office setting versus the hospital outpatient setting.